Analyst Ratings for [MLTX] MoonLake Immunotherapeutics

1/17/25	Upgrades	Neutral Buy	X
MLTX MoonLake Immunotherapeutics Goldman
$62 $82
11/5/24	Resumed	Outperform	X
MLTX MoonLake Immunotherapeutics Wedbush
$92 $73
6/25/24	Initiated	Outperform	X
MLTX MoonLake Immunotherapeutics Oppenheimer
$104
4/2/24	Initiated	Neutral	X
MLTX MoonLake Immunotherapeutics Goldman
$62
2/15/24	Initiated	Outperform	X
MLTX MoonLake Immunotherapeutics Wolfe Research
$77
12/8/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Citigroup
$72
11/2/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Stifel
$74
9/14/23	Downgrades	Buy Neutral	X
MLTX MoonLake Immunotherapeutics Bryan Garnier
8/31/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Needham
$76
6/15/23	Initiated	Equal Weight	X
MLTX MoonLake Immunotherapeutics Barclays
$28
5/1/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Guggenheim
$51
3/22/23	Initiated	Outperform	X
MLTX MoonLake Immunotherapeutics Wedbush
$33
3/9/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics BTIG Research
$36
2/14/23	Initiated	Overweight	X
MLTX MoonLake Immunotherapeutics Cantor Fitzgerald
$23
2/2/23	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Bryan Garnier
$22
11/11/22	Initiated	Buy	X
MLTX MoonLake Immunotherapeutics Jefferies
$16
8/25/22	Initiated	Outperform	X
MLTX MoonLake Immunotherapeutics SVB Leerink
$17
7/7/22	Initiated	Outperform	X
MLTX MoonLake Immunotherapeutics Cowen

MLTX MoonLake Immunotherapeutics

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.